Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F13%3A10188937" target="_blank" >RIV/00216208:11110/13:10188937 - isvavai.cz</a>
Alternative codes found
RIV/00064173:_____/13:N0000026
Result on the web
<a href="http://dx.doi.org/10.1016/S0140-6736(12)62190-4" target="_blank" >http://dx.doi.org/10.1016/S0140-6736(12)62190-4</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/S0140-6736(12)62190-4" target="_blank" >10.1016/S0140-6736(12)62190-4</a>

Result language
angličtina
Original language name
Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial
Original language description
Background: Daclizumab, a humanised monoclonal antibody, modulates interleukin-2 signalling by blocking the ? subunit (CD25) of the interleukin-2 receptor. We assessed whether daclizumab high-yield process (HYP) would be effective when given as monotherapy for a 1 year treatment period in patients with relapsing-remitting multiple sclerosis
Czech name
—
Czech description
—

Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FH - Neurology, neuro-surgery, nuero-sciences
OECD FORD branch
—

Project
—
Continuities
Z - Vyzkumny zamer (s odkazem do CEZ)<br>I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year
2013
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)